Drug Trial News

RSS

New vaccine for post exposure treatment of rabies infection enters human clinical trial

Yisheng Biopharma Co., Ltd., a biopharmaceutical company focusing on the research, development, manufacturing, sales and marketing of vaccine products, announced that a new vaccine for the post exposure treatment of the rabies infection was entering human clinical trial after a six-year long collaboration with a number of research institutes worldwide.

16 Mar 2015

AcelRx announces dosing of first patient in pivotal ARX-04 Phase 3 study for treatment of acute pain

AcelRx Pharmaceuticals, Inc., a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of acute pain, today reported dosing of the first patient in the pivotal Phase 3 study of ARX-04.

16 Mar 2015

Novimmune tests NI-0501 as first-line treatment for hemophagocytic lymphohistiocytosis

Novimmune SA announces that patients diagnosed with hemophagocytic lymphohistiocytosis (HLH), and who are participating in the company's ongoing clinical trial of its NI-0501 monoclonal antibody, will now be able to be treated with the drug without having to first fail conventional treatments.

16 Mar 2015

New antibody treatment blocks immune signaling protein crucial to psoriasis

Many patients suffering from psoriasis showed significant recovery after just a single dose of an experimental treatment with a human antibody that blocks an immune signaling protein crucial to the disease, researchers report.

16 Mar 2015

Results of pacritinib Phase 2 study in myelofibrosis patients published in journal 'Blood'

CTI BioPharma Corp. today announced that results of a Phase 2 study of pacritinib, in patients with myelofibrosis were published in the journal Blood. Pacritinib is a next-generation oral JAK2/FLT3 multikinase inhibitor currently in Phase 3 development in the PERSIST program.

16 Mar 2015

Combined use of enalapril and folic acid can significantly reduce risk of first stroke

In a study that included more than 20,000 adults in China with high blood pressure but without a history of stroke or heart attack, the combined use of the hypertension medication enalapril and folic acid, compared with enalapril alone, significantly reduced the risk of first stroke, according to a study appearing in JAMA. The study is being released to coincide with its presentation at the American College of Cardiology Annual Scientific Session.

16 Mar 2015

Samsung Bioepis submits second biosimilar candidate MAA to EMA

Samsung Bioepis Co., Ltd., today announced that the Marketing Authorization Application (MAA) for SB2, its Remicade (Infliximab) biosimilar candidate, has been submitted to the European Medicines Agency (EMA).

13 Mar 2015

Neuralstem reports top line data from NSI-566 Phase II trial for treatment of ALS

Neuralstem, Inc. announced top line data from the Phase II trial of NSI-566 spinal cord-derived neural stem cells under development for the treatment of amyotrophic lateral sclerosis (ALS). The study met primary safety endpoints. The maximum tolerated dose of 16 million transplanted cells and the surgery was well tolerated.

12 Mar 2015

Promising new natural treatment for Alzheimer's disease nears clinical trial

A promising new natural treatment for Alzheimer's disease is moving toward clinical trials. This will be a major step forward as there is nothing on the market that slows the progression of Alzheimer's.

12 Mar 2015

Existing epilepsy drug reverses aMCI in elderly patients at risk for Alzheimer's disease

A novel therapeutic approach for an existing drug reverses a condition in elderly patients who are at high risk for dementia due to Alzheimer's disease, researchers at Johns Hopkins University found.

12 Mar 2015

Fourth patient dosed in Benitec Biopharma's Phase I/IIa hepatitis C trial

Benitec Biopharma, a biopharmaceutical company focused on providing potentially curative therapies with its proprietary gene-silencing technology called ddRNAi or "expressed RNAi," today announced that the fourth patient in the company's Phase I/IIa dose escalation clinical trial of its lead program TT-034 for treating hepatitis C was dosed at the Duke Clinical Research Unit.

11 Mar 2015

Recruitment completed for Phase III PROUD-PV trial of P1101 for treatment of polycythemia vera

PharmaEssentia (Taipei, Taiwan) and AOP Orphan (Vienna, Austria) announce the completion of recruitment for the Phase III trial PROUD-PV to support global marketing of P1101 (Ropeginterferon alfa-2b), a novel, long-acting, mono-pegylated interferon for the first line treatment of polycythemia vera.

11 Mar 2015

Brain tumor experts launch revolutionary fast-track approach to cancer research

Brain tumor experts at Barrow Neurological Institute at Dignity Health St. Joseph's Hospital and Medical Center have launched a revolutionary fast-track approach to cancer research, giving new hope to brain cancer patients.

10 Mar 2015

Chemotherapy, radiation therapy combination improves outcomes for people with low-grade brain cancer

New clinical-trial findings provide further evidence that combining chemotherapy with radiation therapy is the best treatment for people with a low-grade form of brain cancer. The findings come from a phase II study co-led by a researcher at Ohio State University Comprehensive Cancer Center - Arthur G. James Cancer Hospital and Richard J. Solove Research Institute and researchers at the University of Maryland and at London Regional Cancer Program in Ontario, Canada.

10 Mar 2015

Advanced Cell Diagnostics' RNAscope technology supports biomarker-selected phase 2 clinical trial of Merrimack Pharmaceuticals' MM-121

Advanced Cell Diagnostics, Inc. (ACD) announced today that Merrimack Pharmaceuticals, Inc. is using ACD's RNAscope technology to select patients for its Phase 2 clinical trial of its product candidate MM-121.

From Advanced Cell Diagnostics 9 Mar 2015

Pacritinib for myelofibrosis meets primary endpoint in Phase 3 PERSIST-1 trial

CTI BioPharma Corp. and Baxter International Inc. today announced positive top-line results for the primary endpoint from PERSIST-1, the randomized, controlled Phase 3 registration clinical trial examining pacritinib, a next generation oral JAK2/FLT3 multikinase inhibitor, for the treatment of patients with primary or secondary myelofibrosis.

From Baxter International Inc. 9 Mar 2015

Clinical study launched to evaluate effectiveness of new HCV therapy in Washington, D.C.

Officials from the National Institutes of Health and the city of Washington, D.C., launched a clinical trial to examine whether primary care physicians and other health care providers, such as nurse practitioners and physician assistants, can use a new antiviral therapy as effectively as specialist physicians to treat people with hepatitis C virus (HCV) infection.

9 Mar 2015

Phase 3 trial results show that new testosterone nasal gel is effective and practical

A new testosterone nasal gel raises men's low testosterone levels to normal, with few side effects, according to the results of a phase 3 clinical trial to be presented Saturday at the Endocrine Society's 97th annual meeting in San Diego.

9 Mar 2015

Sunitinib holds promise for treatment of advanced differentiated thyroid cancer

In patients with advanced thyroid cancer, sunitinib, a drug approved for treatment of several other cancers, showed significant cancer-fighting activity t, a new phase 2 clinical trial has found. Results of the single-center study will be presented Sunday at the Endocrine Society's 97th annual meeting in San Diego.

9 Mar 2015

$Investigational drug for postmenopausal osteoporosis reduces rate of new spinal fractures$

Investigational drug for postmenopausal osteoporosis reduces rate of new spinal fractures

Abaloparatide-SC, an injectable drug being studied for the treatment of postmenopausal osteoporosis, reduces the rate of new spinal fractures by a statistically significant 86 percent and as well as statistically significant reductions in the fracture rate at other parts of the body, a phase 3 clinical trial finds. Results of the ACTIVE fracture prevention trial will be described in a late-breaking oral presentation Thursday at the Endocrine Society's 97th annual meeting in San Diego.

9 Mar 2015

Drug Trial News

New vaccine for post exposure treatment of rabies infection enters human clinical trial

AcelRx announces dosing of first patient in pivotal ARX-04 Phase 3 study for treatment of acute pain

Novimmune tests NI-0501 as first-line treatment for hemophagocytic lymphohistiocytosis

New antibody treatment blocks immune signaling protein crucial to psoriasis

Results of pacritinib Phase 2 study in myelofibrosis patients published in journal 'Blood'

Combined use of enalapril and folic acid can significantly reduce risk of first stroke

Samsung Bioepis submits second biosimilar candidate MAA to EMA

Neuralstem reports top line data from NSI-566 Phase II trial for treatment of ALS

Promising new natural treatment for Alzheimer's disease nears clinical trial

Existing epilepsy drug reverses aMCI in elderly patients at risk for Alzheimer's disease

Fourth patient dosed in Benitec Biopharma's Phase I/IIa hepatitis C trial

Recruitment completed for Phase III PROUD-PV trial of P1101 for treatment of polycythemia vera

Brain tumor experts launch revolutionary fast-track approach to cancer research

Chemotherapy, radiation therapy combination improves outcomes for people with low-grade brain cancer

Advanced Cell Diagnostics' RNAscope technology supports biomarker-selected phase 2 clinical trial of Merrimack Pharmaceuticals' MM-121

Pacritinib for myelofibrosis meets primary endpoint in Phase 3 PERSIST-1 trial

Clinical study launched to evaluate effectiveness of new HCV therapy in Washington, D.C.

Phase 3 trial results show that new testosterone nasal gel is effective and practical

Sunitinib holds promise for treatment of advanced differentiated thyroid cancer

Investigational drug for postmenopausal osteoporosis reduces rate of new spinal fractures

Advancing brain microphysiological systems (bMPS)

PhD researcher at LifeArc

Unveiling Hidden Potential: Organoids for Disease Modeling in Neuroscience Research

Latest News